

CITATION REPORT

List of articles citing

Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury

DOI: 10.1016/j.jacc.2018.01.009

Journal of the American College of Cardiology, 2018, 71, 1105-

Source: <https://exaly.com/paper-pdf/68770414/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
33	Resolving Concerns With the Newer Oral Anticoagulant Medications: Is Hepatotoxicity a Real Concern?. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1114-1116	15.1	
32	Oral Anticoagulation in Patients With Liver Disease. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2162-2175	15.1	83
31	Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 179-189	15.1	21
30	[Oral anticoagulation in atrial fibrillation: differential therapy with non vitamin K antagonist oral anticoagulants (NOAC) and vitamin K antagonists (VKA)]. <i>MMW Fortschritte Der Medizin</i> , 2019 , 161, 15-23	9	1
29	Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews. <i>Drug Safety</i> , 2019 , 42, 1409-1422	5.1	8
28	Gastrointestinal and liver diseases and atrial fibrillation: a review of the literature. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284819832237	4.7	7
27	Evolving Roles of Spontaneous Reporting Systems to Assess and Monitor Drug Safety. 2019 ,		7
26	Drug-Induced Liver Injury: Highlights of the Recent Literature. <i>Drug Safety</i> , 2019 , 42, 365-387	5.1	51
25	Oral anticoagulants and risk of acute liver injury in patients with nonvalvular atrial fibrillation: a propensity-weighted nationwide cohort study. <i>Scientific Reports</i> , 2020 , 10, 11624	4.9	6
24	Risk of fracture in patients with non-valvular atrial fibrillation initiating direct oral anticoagulants vs. vitamin K antagonists. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 389-397	6.4	3
23	Author's Reply to Vaz et al.: "Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease". <i>American Journal of Cardiovascular Drugs</i> , 2020 , 20, 507-508	4	
22	Association Between Nonvitamin K Antagonist Oral Anticoagulants or Warfarin and Liver Injury: A Cohort Study. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1513-1524	0.7	6
21	Association between oral anticoagulants and osteoporosis: Real-world data mining using a multi-methodological approach. <i>International Journal of Medical Sciences</i> , 2020 , 17, 471-479	3.7	7
20	Real-world use of nonvitamin K antagonist oral anticoagulant in atrial fibrillation patients with liver disease: A meta-analysis. <i>Clinical Cardiology</i> , 2020 , 43, 676-683	3.3	3
19	Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review. <i>Advances in Therapy</i> , 2020 , 37, 1910-1932	4.1	25
18	Dabigatran Reversal With Idarucizumab in 2 Patients With Portal Vein Thrombosis Undergoing Orthotopic Liver Transplantation. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2021 , 25, 200-207	1.4	0
17	Low rates of liver injury in edoxaban users: Evidence from a territory-wide observational cohort study. <i>Clinical Cardiology</i> , 2021 , 44, 886-889	3.3	1

16	The hemostatic and thrombotic complications of liver disease. <i>European Journal of Haematology</i> , 2021 , 107, 383-392	3.8	1
15	Utilization and long-term persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	
14	Antithrombotic therapy in patients with liver disease: population-based insights on variations in prescribing trends, adherence, persistence and impact on stroke and bleeding. <i>Lancet Regional Health - Europe, The</i> , 2021 , 10, 100222		1
13	Database Studies on Drug-Induced Liver Injury: The Importance of Causality Assessment. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1090-1091	0.7	1
12	Manejo das Hemorragias Relacionadas aos Anticoagulantes Orais de A Direta. <i>Journal of Cardiac Arrhythmias</i> , 2019 , 32, 89-96	0.1	
11	Management of Hemorrhage Related to Direct Action Oral Anticoagulant Medication. <i>Journal of Cardiac Arrhythmias</i> , 2019 , 32, 89-96	0.1	
10	Nonvitamin K Antagonist Oral Anticoagulants Reduced the Risk of Liver Injury in Atrial Fibrillation Patients. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1090	0.7	
9	Response to Liu et al., and Bjnsson and Bjnsson. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1091-1092	0.7	1
8	Current Observations in the Management of Hypo- and Hypercoagulability in Patients With Acute or Chronic Liver Failure. <i>Gastroenterology and Hepatology</i> , 2021 , 17, 23-26	0.7	
7	2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. <i>Journal of Arrhythmia</i> , 2021 , 37, 1389-1426	1.5	8
6	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with advanced chronic kidney and liver diseases.. <i>European Heart Journal Supplements</i> , 2022 , 24, A11-A18	1.5	
5	Apixaban-Induced Hepatotoxicity.. <i>Cureus</i> , 2022 , 14, e23879	1.2	
4	Anticoagulation in Cirrhosis: Evidence for the Treatment of Portal Vein Thrombosis and Applications for Prophylactic Therapy.. <i>Journal of Clinical Gastroenterology</i> , 2022 ,	3	0
3	Stroke Prevention in Atrial Fibrillation. 2022 ,		
2	Interstitial Lung Disease With Nonitamin K Oral Anticoagulants Clinical Concern?. 2022 , 5, e2243316		0
1	Cardiovascular assessment before liver transplantation. 2023 , 309-326		0